News headlines about Cidara Therapeutics (NASDAQ:CDTX) have trended positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cidara Therapeutics earned a media sentiment score of 0.30 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 44.9603879636003 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s scoring:
- Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin (globenewswire.com)
- Blog Exposure – Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin (finance.yahoo.com)
- Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin (finance.yahoo.com)
- Cidara Therapeutics Sinks Despite Positive Midstage Results (247wallst.com)
- Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin (finance.yahoo.com)
Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald set a $15.00 target price on shares of Cidara Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 8th. Zacks Investment Research downgraded shares of Cidara Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, December 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $13.56.
Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.05. research analysts expect that Cidara Therapeutics will post -2.6 earnings per share for the current year.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.